Paramjit Kalirao, MD
Nephrology · Lauderdale Lakes, FLNPI 1497943856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,069, 2.0 times the $528 reported in 2019.
Across 215 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$796
- Travere Therapeutics, Inc.$685
- Amgen$658
- Calliditas Therapeutics US Inc.$297
- Otsuka America Pharmaceutical, Inc.$295
- Vifor Pharma, Inc.$287
- plus $2K from 25 others
Across 725 payments — averaging $1271.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$613K
- GSK$309K
What the payments were for
- Food & beverage$4,95099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $796 |
| Travere Therapeutics, Inc. | 31 | $685 |
| Amgen(2 entities) | 24 | $658 |
| Calliditas Therapeutics US Inc. | 12 | $297 |
| Otsuka America Pharmaceutical, Inc. | 14 | $295 |
| Vifor Pharma, Inc. | 12 | $287 |
| Bayer | 17 | $274 |
| Akebia Therapeutics Inc | 9 | $210 |
| GSK | 3 | $167 |
| Fresenius USA Marketing, Inc. | 9 | $159 |
| Aurinia Pharma U.S., Inc. | 7 | $157 |
| Mallinckrodt Hospital Products Inc. | 4 | $132 |
| Pfizer | 1 | $125 |
| Boehringer Ingelheim | 4 | $83 |
| Ardelyx, Inc. | 3 | $71 |
| Novo Nordisk | 3 | $65 |
| UCB, Inc. | 2 | $65 |
| Novartis | 3 | $59 |
| Medtronic(2 entities) | 3 | $57 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Mallinckrodt Enterprises LLC | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Lilly USA, LLC | 2 | $38 |
| Eisai Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Biogen | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,981 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 79 | $88,657 |
| KerendiaFinerenone | 67 | $76,061 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $32,274 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $31,636 |
| ProcritEpoetin Alfa | 11 | $12,475 |
| Sevelamer Carbonate | 35 | $5,855 |
| Clonidine | 27 | $3,385 |
| Losartan Potassium | 123 | $1,455 |
| Calcium Acetate | 18 | $1,441 |
| Bumetanide | 26 | $1,388 |
| Calcitriol | 89 | $1,199 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,161 |
| Hydralazine Hcl | 49 | $942 |
| Febuxostat | 11 | $879 |
| Nifedipine ErNifedipine | 36 | $832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $796 | $120,293112 claims |
| BayerKerendia | $274 | $76,06167 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $50 | $19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.
Other nephrology in Lauderdale Lakes
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.